Fed. Circ. Backs Sanofi, Regeneron PTAB Win Over Amgen
Law360 (October 13, 2020, 7:33 PM EDT) -- The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision invalidating an Amgen unit's patent on treating inflammatory disorders, in a win for Sanofi and Regeneron, whose eczema and asthma treatment Dupixent was accused of infringement.
The appeals court rejected an argument by Amgen's Immunex subsidiary that the PTAB's inter partes review decision was based on an incorrect holding that in the context of the patent, the phrase "human antibodies" can refer to those that are only partially human. The Federal Circuit said the evidence shows the board got it right.
The court said in its precedential opinion...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!